Safety and efficacy of ocrelizumab in combination with methotrexate in MTX-naive subjects with rheumatoid arthritis: The phase III FILM trial

Annals of the Rheumatic Diseases

Volumn 71, Issue 8, 2012, Pages 1289-1296

  Stohl, William ^a   Gomez Reino, Juan ^b   Olech, Ewa ^c   Dudler, Jean ^d   Fleischmann, Roy M ^e   Zerbini, Cristiano A F ^f   Ashrafzadeh, Ali ^g   Grzeschik, Susanna ^g   Bieraugel, Rebecca ^h   Green, Jennifer ^h   Francom, Steven ^g   Dummer, Wolfgang ^g  

^a LAC USC MEDICAL CENTER   (United States)

^b University Hospital of Santiago de Compostela   (Spain)

^c UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^d Hopital Cantonal de Fribourg   (Switzerland)

^e UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^f Centro Paulista de Investigacao Clinica   (Brazil)

^g GENENTECH INC   (United States)

^h ROCHE PRODUCTS LTD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

METHOTREXATE; OCRELIZUMAB; PLACEBO;

ACUTE HEART INFARCTION; ACUTE RESPIRATORY FAILURE; ADULT; AGED; ARTICLE; BLOOD TOXICITY; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CANDIDIASIS; CHICKENPOX; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL DISEASE; HEART DISEASE; HISTOPLASMOSIS; HUMAN; INFECTION; INFUSION RELATED REACTION; INJURY; JOINT INJURY; LYMPHATIC SYSTEM DISEASE; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; NEOPLASM; PARALLEL DESIGN; PNEUMONIA; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; SIDE EFFECT; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME; TUBERCULOSIS; URINARY TRACT INFECTION; VIRUS PNEUMONIA;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOCOMPROMISED HOST; INFECTION; INFUSIONS, INTRAVENOUS; JOINTS; MALE; METHOTREXATE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84863841745     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2011-200706     Document Type: Article

References (12)

1. St Clair EW, van der Heijde DM, Smolen JS, et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 2004;50:3432-43. (Pubitemid 39488667)
2. Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006;54:26-37. (Pubitemid 43122183)
3. Emery P, Breedveld FC, Hall S, et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet 2008;372:375-82.
4. Edwards JC, Szczepański L, Szechiński J, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004;350:2572-81. (Pubitemid 38758544)
5. Emery P, Fleischmann R, Filipowicz-Sosnowska A, et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 2006;54:1390-400.
6. Cohen SB, Emery P, Greenwald MW, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006;54:2793-806. (Pubitemid 44497758)
7. Tak PP, Rigby WF, Rubbert-Roth A, et al. Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial. Ann Rheum Dis 2011;70:39-46.
8. Genovese MC, Kaine JL, Lowenstein MB, et al. Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I/II randomized, blinded, placebo-controlled, dose-ranging study. Arthritis Rheum 2008;58:2652-61.
9. Rigby W, Tony H-P, Oelke K, et al. Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: the phase III STAGE trial. Arthritis Rheum 2011 Sep 8 [Epub ahead of print].
10. Tak PP, Mease PJ, Genovese MC, et al. Safety and efficacy of Ocrelizumab in patients with rheumatoid arthritis with an inadequate response to at least one TNF inhibitor: the Phase III SCRIPT Trial. Arthritis Rheum 2012;(In Press).
11. Felson DT, Anderson JJ, Boers M, et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. Arthritis Rheum 1993;36:729-40. (Pubitemid 23175613)
12. rd, et al. Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials. J Rheumatol 2010;37:558-67.